{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000008","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.743049+00:00","generated_at":"2026-06-05T22:29:14.026074+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF","bullets":["Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).","Adverse events included burns, hematoma, hypertrophic scar, and seroma; Renuvion group had significantly less.","Renuvion featured in three educational sessions at AACS 40th Annual Scientific Meeting, Feb 22-24, 2024.","Dr. Michael Kluska presents the study; CEO Charlie Goodwin highlights expansion of clinical evidence supporting safety."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000008","json":"https://secwatch.observer/filing/0000719135-24-000008.json","markdown":"https://secwatch.observer/filing/0000719135-24-000008.md","text":"https://secwatch.observer/filing/0000719135-24-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/0000719135-24-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/apyx-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:29:14.026074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}